European Urology Oncology

Slides:

Advertisements

Similar presentations

PSSA Cohort Analysis by CORE AREAS Classes:

Advertisements

Early Detection of Prostate Cancer in 2007

Volume 56, Issue 5, Pages (November 2009)

Volume 55, Issue 1, Pages 1-8 (January 2009)

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit Pim J. van Leeuwen, David Connolly, Anna.

Volume 57, Issue 1, Pages (January 2010)

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

Volume 67, Issue 1, Pages (January 2015)

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database

European Urology Oncology

Volume 61, Issue 2, Pages (February 2012)

Prostate Cancer Epidemic in Sight?

Volume 61, Issue 3, Pages (March 2012)

Volume 63, Issue 4, Pages (April 2013)

European Urology Oncology

European Urology Oncology

Volume 60, Issue 5, Pages (November 2011)

European Urology Oncology

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal.

Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis Mohamad B. Sonbol, Belal Firwana, Talal.

Volume 68, Issue 3, Pages (September 2015)

Volume 56, Issue 2, Pages (August 2009)

Volume 59, Issue 4, Pages (April 2011)

Volume 69, Issue 6, Pages (June 2016)

European Urology Oncology

European Urology Oncology

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Volume 54, Issue 2, Pages (August 2008)

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer Epidemic in Sight?

Rectal Injury During Radical Prostatectomy: Focus on Robotic Surgery

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter,

Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL,

Tillmann Loch, Pat Fox Fulgham European Urology

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 64, Issue 4, Pages (October 2013)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

European Urology Oncology

European Urology Oncology

European Urology Oncology

Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective,

European Urology Oncology

European Urology Oncology

European Urology Oncology

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study Andrew M. Erickson, Stefano Luzzago, Axel.

Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review Alexey Surov, Hans Jonas Meyer, Andreas.

The Cost to Medicare of Bladder Cancer Care

Maria Erali, David C. Pattison, Carl T. Wittwer, Cathy A. Petti

European Urology Oncology

The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy Neal Patel, Eliza Cricco-Lizza,

European Urology Oncology

Volume 52, Issue 6, Pages (December 2007)

European Urology Oncology

Volume 54, Issue 3, Pages (September 2008)

European Urology Oncology

European Urology Oncology

Does PSA Testing Influence the Natural History of Prostate Cancer?

European Urology Oncology

European Urology Oncology

European Urology Oncology

Maximilian Burger, Ashish M. Kamat, David McConkey

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

European Urology Oncology

Presentation transcript:

European Urology Oncology Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies Theo H. van der Kwast, Jozien Helleman, Daan Nieboer, Sophie M. Bruinsma, Monique J. Roobol European Urology Oncology DOI: 10.1016/j.euo.2018.08.017 Copyright © 2018 Terms and Conditions

Fig. 1 (A) The discrepancy rate of grading GG1 versus GG≥2 and (B) tissue length (mm) of the biopsy cores after a centralized pathological review of 445 biopsies originating from 15 centers within the GAP3 consortium (cohorts A–O). Box in Figure 1B represents the 25–75th percentile, the whiskers represent 1.5 times the difference between the 25th and the 75th percentile, and the dots are outliers. GG=grade group. European Urology Oncology DOI: (10.1016/j.euo.2018.08.017) Copyright © 2018 Terms and Conditions